Trial ID or NCT#



not recruiting iconNOT RECRUITING


This is a Phase 1b/2 study of AVB-S6-500 in combination with pegylated liposomal doxorubicin (PLD) or paclitaxel (Pac) in patients with platinum resistant recurrent ovarian cancer. The phase 1b portion of the study is open label and patients will receive either AVB-S6-500+PLD or AVB-S6-500+ Pac. The Phase 2 portion of the study is randomized, double-blind, placebo-controlled study to compare efficacy and tolerability of AVB-S6-500 in combination with PLD or Pac versus placebo plus PLD or Pac.

Official Title

A Phase 1b/2 Randomized, Controlled Study of AVB-S6-500 in Combination With Pegylated Liposomal Doxorubicin (PLD) or Paclitaxel (Pac) in Patients With Platinum-resistant Recurrent Ovarian Cancer

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: Female
Accepts Healthy Volunteers: No


Elisabeth Jenefer Diver
Elisabeth Jenefer Diver
Gynecologic oncologist, Gynecologic oncologist, Minimally invasive gynecologic surgeon
Clinical Assistant Professor, Obstetrics & Gynecology - Gynecologic Oncology

Contact us to find out if this trial is right for you.


Nimna Ranatunga
(650) 721-4070